Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery

doi:10.1046/j.1365-2125.1998.00035.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

British Journal of Clinical Pharmacology

Volume 46 Issue 1, Pages 37 - 43

Published Online: 4 Jan 2002

The Journal of The British Pharmacological Society

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 144K) | Related Articles | Citation Tracking

Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery

Laurence E. Mather ¹ , Annie Woodhouse ¹ , M. Elizabeth Ward ¹ , Stephen J. Farr ² , Reid A. Rubsamen ² & Lorne G. Eltherington ²

¹ Department of Anaesthesia and Pain Management, University of Sydney at Royal North Shore Hospital, St Leonards, NSW 2065, Australia, ² Aradigm Corporation, 26219 Eden Landing Road, Hayward, CA 94545, USA

Correspondence to Professor L. E. Mather, Department of Anaesthesia and Pain Management, University of Sydney at Royal North Shore Hospital, St Leonards, NSW 2065, Australia.

KEYWORDS

bioavailability • fentanyl • pharmacokinetics • pulmonary administration

ABSTRACT

Aims Pulmonary drug delivery is a promising noninvasive method of systemic administration. Our aim was to determine whether a novel breath-actuated, microprocessor-controlled metered dose oral inhaler (SmartMist^TM, Aradigm Corporation) could deliver fentanyl in a way suitable for control of severe pain.

Methods Aersolised pulmonary fentanyl base 100–300 μg was administered to healthy volunteers using SmartMist^TM and the resultant plasma concentration-time data were compared with those from the same doses administered by intravenous (i.v.) injection in the same subjects.

Results Plasma concentrations from SmartMist^TM were similar to those from i.v. injection. Time-averaged bioavailability based upon nominal doses averaged 100%, and was >50% within 5 min of delivery. Fentanyl systemic pharmacokinetics were similar to those previously reported with no trends to dose-dependence from either route. Side-effects (e.g. sedation, lightheadedness) were the same from both routes.

Conclusions Fentanyl delivery using SmartMist^TM can provide analgetically relevant plasma drug concentrations. This, combined with its ease of noninvasive use and transportability, suggests a strong potential for field and domicilliary use, and for patient controlled analgesia without the need for i.v. cannulae.

DIGITAL OBJECT IDENTIFIER (DOI)

10.1046/j.1365-2125.1998.00035.x About DOI